- Home
- VNDA vs RCEL Comparison
VNDA vs RCEL Comparison
Compare VNDA & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- RCEL
- Stock Information
- Founded
- VNDA 2002
- RCEL 2020
- Country
- VNDA United States
- RCEL United States
- Employees
- VNDA N/A
- RCEL N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- VNDA Health Care
- RCEL Health Care
- Exchange
- VNDA Nasdaq
- RCEL Nasdaq
- Market Cap
- VNDA 270.2M
- RCEL 310.6M
- IPO Year
- VNDA 2006
- RCEL N/A
- Fundamental
- Price
- VNDA $4.94
- RCEL $12.87
- Analyst Decision
- VNDA Strong Buy
- RCEL Hold
- Analyst Count
- VNDA 2
- RCEL 3
- Target Price
- VNDA $15.50
- RCEL $16.50
- AVG Volume (30 Days)
- VNDA 643.5K
- RCEL 112.9K
- Earning Date
- VNDA 11-06-2024
- RCEL 11-07-2024
- Dividend Yield
- VNDA N/A
- RCEL N/A
- EPS Growth
- VNDA N/A
- RCEL N/A
- EPS
- VNDA N/A
- RCEL N/A
- Revenue
- VNDA $190,858,000.00
- RCEL $60,040,000.00
- Revenue This Year
- VNDA $5.13
- RCEL $34.73
- Revenue Next Year
- VNDA $42.65
- RCEL $54.61
- P/E Ratio
- VNDA N/A
- RCEL N/A
- Revenue Growth
- VNDA N/A
- RCEL 32.24
- 52 Week Low
- VNDA $3.46
- RCEL $7.51
- 52 Week High
- VNDA $6.75
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- VNDA 50.36
- RCEL 64.34
- Support Level
- VNDA $4.82
- RCEL $11.63
- Resistance Level
- VNDA $5.55
- RCEL $13.82
- Average True Range (ATR)
- VNDA 0.22
- RCEL 0.86
- MACD
- VNDA -0.02
- RCEL 0.09
- Stochastic Oscillator
- VNDA 32.22
- RCEL 74.46
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.